In vivo genome editing partially restores alpha1-antitrypsin in a murine model of AAT deficiency
Authors
Song, Chun-QingWang, Dan
Jiang, Tingting
O'Connor, Kevin
Tang, Qiushi
Cai, Lingling
Li, Xiangrui
Weng, Zhiping
Yin, Hao
Gao, Guangping
Mueller, Christian
Flotte, Terence R.
Xue, Wen
UMass Chan Affiliations
Department of Molecular, Cell and Cancer BiologyProgram in Molecular Medicine
Program in Bioinformatics and Integrative Biology
Department of Microbiology and Physiological Systems
Horae Gene Therapy Center
RNA Therapeutics Institute
Department of Pediatrics, Division of Pediatric Pulmonology
Document Type
Journal ArticlePublication Date
2018-03-29Keywords
BioinformaticsBiomedical Engineering and Bioengineering
Computational Biology
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Genomics
Therapeutics
Metadata
Show full item recordAbstract
CRISPR genome editing holds promise in the treatment of genetic diseases that currently lack effective long-term therapies. Patients with Alpha-1 Antitrypsin (AAT) deficiency develop progressive lung disease due to the loss of AAT's antiprotease function and liver disease due to a toxic gain of function of the common mutant allele. However, it remains unknown whether CRISPR-mediated AAT correction in the liver, where AAT is primarily expressed, can correct either or both defects. Here we show that AAV delivery of CRISPR can effectively correct Z-AAT mutation in the liver of a transgenic mouse model. Specifically, we co-injected two AAV: one expressing Cas9 and another encoding an AAT guide RNA and homology-dependent repair template. In both neonate and adult mice, this treatment partially restored M-AAT in the serum. Furthermore, deep sequencing confirmed both indel mutations and precise gene correction in the liver, permitting careful analysis of gene editing events in vivo. This study demonstrates a proof-of-concept for the application of CRISPR-Cas9 technology to correct AAT mutations in vivo and validates continued exploration of this approach for the treatment of patients with AAT deficiency.Source
Hum Gene Ther. 2018 Mar 29. doi: 10.1089/hum.2017.225. Link to article on publisher's site
DOI
10.1089/hum.2017.225Permanent Link to this Item
http://hdl.handle.net/20.500.14038/43636PubMed ID
29597895Related Resources
ae974a485f413a2113503eed53cd6c53
10.1089/hum.2017.225